Cargando…

Reduced Renal α-Klotho Expression in CKD Patients and Its Effect on Renal Phosphate Handling and Vitamin D Metabolism

Renal α-Klotho (α-KL) plays a fundamental role as a co-receptor for fibroblast growth factor 23 (FGF23), a phosphaturic hormone and regulator of 1,25(OH)(2) vitamin D(3) (1,25VitD(3)). Disruption of FGF23-α-KL signaling is thought to be an early hallmark of chronic kidney disease (CKD) involving red...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakan, Hirokazu, Nakatani, Kimihiko, Asai, Osamu, Imura, Akihiro, Tanaka, Tomohiro, Yoshimoto, Shuhei, Iwamoto, Noriyuki, Kurumatani, Norio, Iwano, Masayuki, Nabeshima, Yo-ichi, Konishi, Noboru, Saito, Yoshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3900516/
https://www.ncbi.nlm.nih.gov/pubmed/24466013
http://dx.doi.org/10.1371/journal.pone.0086301
_version_ 1782300708951818240
author Sakan, Hirokazu
Nakatani, Kimihiko
Asai, Osamu
Imura, Akihiro
Tanaka, Tomohiro
Yoshimoto, Shuhei
Iwamoto, Noriyuki
Kurumatani, Norio
Iwano, Masayuki
Nabeshima, Yo-ichi
Konishi, Noboru
Saito, Yoshihiko
author_facet Sakan, Hirokazu
Nakatani, Kimihiko
Asai, Osamu
Imura, Akihiro
Tanaka, Tomohiro
Yoshimoto, Shuhei
Iwamoto, Noriyuki
Kurumatani, Norio
Iwano, Masayuki
Nabeshima, Yo-ichi
Konishi, Noboru
Saito, Yoshihiko
author_sort Sakan, Hirokazu
collection PubMed
description Renal α-Klotho (α-KL) plays a fundamental role as a co-receptor for fibroblast growth factor 23 (FGF23), a phosphaturic hormone and regulator of 1,25(OH)(2) vitamin D(3) (1,25VitD(3)). Disruption of FGF23-α-KL signaling is thought to be an early hallmark of chronic kidney disease (CKD) involving reduced renal α-KL expression and a reciprocal rise in serum FGF23. It remains unclear, however, whether the rise in FGF23 is related to the loss of renal α-KL. We evaluated α-KL expression in renal biopsy samples and measured levels of several parameters of mineral metabolism, as well as soluble α-KL (sKL), in serum and urinary samples from CKD patients (n = 236). We found that although renal α-KL levels were significantly reduced and serum FGF23 levels were significantly elevated in early and intermediate CKD, serum phosphate levels remained within the normal range. Multiple regression analysis showed that the increases in FGF23 were significantly associated with reduced renal function and elevated serum phosphate, but were not associated with loss of renal α-KL. Moreover, despite falling renal α-KL levels, the increase in FGF23 enhanced urinary fractional excretion of phosphate and reduced serum 1,25VitD(3) levels in early and intermediate CKD, though not in advanced CKD. Serum sKL levels also fell significantly over the course of CKD, and renal α-KL was a significant independent determinant of sKL. These results demonstrate that FGF23 levels rise to compensate for renal failure-related phosphate retention in early and intermediate CKD. This enables FGF23-α-KL signaling and a neutral phosphate balance to be maintained despite the reduction in α-KL. In advanced CKD, however, renal α-KL declines further. This disrupts FGF23 signaling, and serum phosphate levels significantly increase, stimulating greater FGF23 secretion. Our results also suggest the serum sKL concentration may be a useful marker of renal α-KL expression levels.
format Online
Article
Text
id pubmed-3900516
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-39005162014-01-24 Reduced Renal α-Klotho Expression in CKD Patients and Its Effect on Renal Phosphate Handling and Vitamin D Metabolism Sakan, Hirokazu Nakatani, Kimihiko Asai, Osamu Imura, Akihiro Tanaka, Tomohiro Yoshimoto, Shuhei Iwamoto, Noriyuki Kurumatani, Norio Iwano, Masayuki Nabeshima, Yo-ichi Konishi, Noboru Saito, Yoshihiko PLoS One Research Article Renal α-Klotho (α-KL) plays a fundamental role as a co-receptor for fibroblast growth factor 23 (FGF23), a phosphaturic hormone and regulator of 1,25(OH)(2) vitamin D(3) (1,25VitD(3)). Disruption of FGF23-α-KL signaling is thought to be an early hallmark of chronic kidney disease (CKD) involving reduced renal α-KL expression and a reciprocal rise in serum FGF23. It remains unclear, however, whether the rise in FGF23 is related to the loss of renal α-KL. We evaluated α-KL expression in renal biopsy samples and measured levels of several parameters of mineral metabolism, as well as soluble α-KL (sKL), in serum and urinary samples from CKD patients (n = 236). We found that although renal α-KL levels were significantly reduced and serum FGF23 levels were significantly elevated in early and intermediate CKD, serum phosphate levels remained within the normal range. Multiple regression analysis showed that the increases in FGF23 were significantly associated with reduced renal function and elevated serum phosphate, but were not associated with loss of renal α-KL. Moreover, despite falling renal α-KL levels, the increase in FGF23 enhanced urinary fractional excretion of phosphate and reduced serum 1,25VitD(3) levels in early and intermediate CKD, though not in advanced CKD. Serum sKL levels also fell significantly over the course of CKD, and renal α-KL was a significant independent determinant of sKL. These results demonstrate that FGF23 levels rise to compensate for renal failure-related phosphate retention in early and intermediate CKD. This enables FGF23-α-KL signaling and a neutral phosphate balance to be maintained despite the reduction in α-KL. In advanced CKD, however, renal α-KL declines further. This disrupts FGF23 signaling, and serum phosphate levels significantly increase, stimulating greater FGF23 secretion. Our results also suggest the serum sKL concentration may be a useful marker of renal α-KL expression levels. Public Library of Science 2014-01-23 /pmc/articles/PMC3900516/ /pubmed/24466013 http://dx.doi.org/10.1371/journal.pone.0086301 Text en © 2014 Sakan et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Sakan, Hirokazu
Nakatani, Kimihiko
Asai, Osamu
Imura, Akihiro
Tanaka, Tomohiro
Yoshimoto, Shuhei
Iwamoto, Noriyuki
Kurumatani, Norio
Iwano, Masayuki
Nabeshima, Yo-ichi
Konishi, Noboru
Saito, Yoshihiko
Reduced Renal α-Klotho Expression in CKD Patients and Its Effect on Renal Phosphate Handling and Vitamin D Metabolism
title Reduced Renal α-Klotho Expression in CKD Patients and Its Effect on Renal Phosphate Handling and Vitamin D Metabolism
title_full Reduced Renal α-Klotho Expression in CKD Patients and Its Effect on Renal Phosphate Handling and Vitamin D Metabolism
title_fullStr Reduced Renal α-Klotho Expression in CKD Patients and Its Effect on Renal Phosphate Handling and Vitamin D Metabolism
title_full_unstemmed Reduced Renal α-Klotho Expression in CKD Patients and Its Effect on Renal Phosphate Handling and Vitamin D Metabolism
title_short Reduced Renal α-Klotho Expression in CKD Patients and Its Effect on Renal Phosphate Handling and Vitamin D Metabolism
title_sort reduced renal α-klotho expression in ckd patients and its effect on renal phosphate handling and vitamin d metabolism
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3900516/
https://www.ncbi.nlm.nih.gov/pubmed/24466013
http://dx.doi.org/10.1371/journal.pone.0086301
work_keys_str_mv AT sakanhirokazu reducedrenalaklothoexpressioninckdpatientsanditseffectonrenalphosphatehandlingandvitamindmetabolism
AT nakatanikimihiko reducedrenalaklothoexpressioninckdpatientsanditseffectonrenalphosphatehandlingandvitamindmetabolism
AT asaiosamu reducedrenalaklothoexpressioninckdpatientsanditseffectonrenalphosphatehandlingandvitamindmetabolism
AT imuraakihiro reducedrenalaklothoexpressioninckdpatientsanditseffectonrenalphosphatehandlingandvitamindmetabolism
AT tanakatomohiro reducedrenalaklothoexpressioninckdpatientsanditseffectonrenalphosphatehandlingandvitamindmetabolism
AT yoshimotoshuhei reducedrenalaklothoexpressioninckdpatientsanditseffectonrenalphosphatehandlingandvitamindmetabolism
AT iwamotonoriyuki reducedrenalaklothoexpressioninckdpatientsanditseffectonrenalphosphatehandlingandvitamindmetabolism
AT kurumataninorio reducedrenalaklothoexpressioninckdpatientsanditseffectonrenalphosphatehandlingandvitamindmetabolism
AT iwanomasayuki reducedrenalaklothoexpressioninckdpatientsanditseffectonrenalphosphatehandlingandvitamindmetabolism
AT nabeshimayoichi reducedrenalaklothoexpressioninckdpatientsanditseffectonrenalphosphatehandlingandvitamindmetabolism
AT konishinoboru reducedrenalaklothoexpressioninckdpatientsanditseffectonrenalphosphatehandlingandvitamindmetabolism
AT saitoyoshihiko reducedrenalaklothoexpressioninckdpatientsanditseffectonrenalphosphatehandlingandvitamindmetabolism